Edwards Lifesciences (EW) Stock Forecast & Price Target

Compare

1,893 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

EW Analyst Ratings

Moderate Buy

15 Buy

9 Hold

0 Sell

Based on 24 analysts giving stock ratings to

Edwards

Lifesciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

EW Stock 12 Month Forecast

Average Price Target

$88.86

▲(9.18% Upside)

Based on 24 Wall Street analysts offering 12 month price targets for Edwards Lifesciences in the last 3 months. The average price target is $88.86 with a high forecast of $101.00 and a low forecast of $80.00. The average price target represents a 9.18% change from the last price of $81.39.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"60":"$60","81":"$81","102":"$102","70.5":"$70.5","91.5":"$91.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":101,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$101.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":88.86,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$88.86</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":80,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$80.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[60,70.5,81,91.5,102],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,79.33,80.99692307692308,82.66384615384615,84.33076923076923,85.9976923076923,87.66461538461539,89.33153846153846,90.99846153846154,92.66538461538461,94.3323076923077,95.99923076923076,97.66615384615385,99.33307692307693,{"y":101,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,79.33,80.06307692307692,80.79615384615384,81.52923076923076,82.26230769230769,82.99538461538461,83.72846153846154,84.46153846153847,85.19461538461539,85.92769230769231,86.66076923076923,87.39384615384616,88.12692307692308,{"y":88.86,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,79.33,79.38153846153845,79.43307692307692,79.48461538461538,79.53615384615385,79.58769230769231,79.63923076923076,79.69076923076923,79.74230769230769,79.79384615384615,79.84538461538462,79.89692307692307,79.94846153846154,{"y":80,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":61.86,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.96,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.1,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.54,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.53,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 43, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.03,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.45,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.62,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.87,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.18,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.1,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.18,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.33,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$101.00

Average Price Target$88.86

Lowest Price Target$80.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Mike Kratky

Leerink Partners

$84→$85

Hold

4.44%

Upside

Reiterated

08/20/25

Leerink Partners Keeps Their Hold Rating on Edwards Lifesciences (EW)Leerink Partners analyst Mike Kratky raised the price target on Edwards Lifesciences (NYSE: EW) to $85.00 (from $84.00) while maintaining a Market Perform rating.

Shagun Singh Chadha

RBC Capital

$89

Buy

9.35%

Upside

Reiterated

08/19/25

Edwards Lifesciences (EW) Receives a Buy from RBC Capital

David Toung

Argus Research

―

Buy

―

Reiterated

08/11/25

Argus Research Remains a Buy on Edwards Lifesciences (EW)We like the growth opportunities for Edwards Lifesciences Corp. (NYSE: EW), as it is a leader in the fast-growing markets for the repair and replacement of heart valves. Edwards makes devices that are implanted through catheter-based minimally invasive procedures and through surgery. These solutions repair the heart’s aortic, mitral, and tricuspid valves. Edwards has substantial growth opportunities. Its transcatheter aortic valve replacement (TAVR) devices are focused on a large addressable market. The global TAVR market is projected to grow around 7% CAGR to $10 billion-$11 billion by 2030, according to market intelligence sources. Edwards’ devices treat aortic stenosis (AS), a narrowing of the aortic valve due to calcium deposits that prevents valve leaflets from opening and closing properly, impeding blood flow.

Adam Maeder

Piper Sandler

$90

Buy

10.58%

Upside

Reiterated

08/07/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Larry Biegelsen

Wells Fargo

$84→$88

Buy

8.12%

Upside

Reiterated

08/07/25

Wells Fargo Reaffirms Their Buy Rating on Edwards Lifesciences (EW)

David Rescott

Robert W. Baird

$79→$81

Hold

-0.48%

Downside

Reiterated

08/07/25

Edwards Lifesciences (EW) Receives a Hold from Robert W. Baird

Robbie Marcus

J.P. Morgan

―

Hold

―

Reiterated

08/06/25

Edwards Lifesciences: Hold Rating Maintained Amid JenaValve Acquisition Delay

Brandon Vazquez

William Blair

―

Buy

―

Reiterated

08/06/25

Edwards Lifesciences: Strong Growth Prospects Amid Regulatory Challenges

Narumi Nakagiri

Daiwa

$89

Buy

9.35%

Upside

Upgraded

07/29/25

Edwards Lifesciences upgraded to Outperform from Neutral at DaiwaEdwards Lifesciences upgraded to Outperform from Neutral at Daiwa

Marie Thibault

BTIG

$100

Buy

22.87%

Upside

Upgraded

07/29/25

Edwards Lifesciences upgraded to Buy from Neutral at BTIGEdwards Lifesciences upgraded to Buy from Neutral at BTIG

Lee Hambright

Bernstein

$80→$85

Hold

4.44%

Upside

Reiterated

07/28/25

Edwards Lifesciences (EW) Receives a Hold from BernsteinBernstein SocGen Group analyst Lee Hambright raised the price target on Edwards Lifesciences (NYSE: EW) to $85.00 (from $80.00) while maintaining a Market Perform rating.

Unknown Analyst

UBS

Not Ranked

UBS

$80→$85

Hold

4.44%

Upside

Reiterated

07/28/25

UBS Sticks to Its Hold Rating for Edwards Lifesciences (EW)

Richard Newitter

Truist Financial

$81→$82

Hold

0.75%

Upside

Reiterated

07/25/25

Truist Financial Reaffirms Their Hold Rating on Edwards Lifesciences (EW)

Suraj Kalia

Oppenheimer

$90

Buy

10.58%

Upside

Reiterated

07/25/25

Edwards Lifesciences (EW) Gets a Buy from Oppenheimer

Pito Chickering

Deutsche Bank

$85→$94

Buy

15.49%

Upside

Reiterated

07/25/25

Edwards Lifesciences price target raised to $94 from $85 at Deutsche BankEdwards Lifesciences price target raised to $94 from $85 at Deutsche Bank

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Mike Kratky

Leerink Partners

$84→$85

Hold

4.44%

Upside

Reiterated

08/20/25

Shagun Singh Chadha

RBC Capital

$89

Buy

9.35%

Upside

Reiterated

08/19/25

Edwards Lifesciences (EW) Receives a Buy from RBC Capital

David Toung

Argus Research

―

Buy

―

Reiterated

08/11/25

Adam Maeder

Piper Sandler

$90

Buy

10.58%

Upside

Reiterated

08/07/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Larry Biegelsen

Wells Fargo

$84→$88

Buy

8.12%

Upside

Reiterated

08/07/25

Wells Fargo Reaffirms Their Buy Rating on Edwards Lifesciences (EW)

David Rescott

Robert W. Baird

$79→$81

Hold

-0.48%

Downside

Reiterated

08/07/25

Edwards Lifesciences (EW) Receives a Hold from Robert W. Baird

Robbie Marcus

J.P. Morgan

―

Hold

―

Reiterated

08/06/25

Edwards Lifesciences: Hold Rating Maintained Amid JenaValve Acquisition Delay

Brandon Vazquez

William Blair

―

Buy

―

Reiterated

08/06/25

Edwards Lifesciences: Strong Growth Prospects Amid Regulatory Challenges

Narumi Nakagiri

Daiwa

$89

Buy

9.35%

Upside

Upgraded

07/29/25

Edwards Lifesciences upgraded to Outperform from Neutral at DaiwaEdwards Lifesciences upgraded to Outperform from Neutral at Daiwa

Marie Thibault

BTIG

$100

Buy

22.87%

Upside

Upgraded

07/29/25

Edwards Lifesciences upgraded to Buy from Neutral at BTIGEdwards Lifesciences upgraded to Buy from Neutral at BTIG

Lee Hambright

Bernstein

$80→$85

Hold

4.44%

Upside

Reiterated

07/28/25

Unknown Analyst

UBS

Not Ranked

UBS

$80→$85

Hold

4.44%

Upside

Reiterated

07/28/25

UBS Sticks to Its Hold Rating for Edwards Lifesciences (EW)

Richard Newitter

Truist Financial

$81→$82

Hold

0.75%

Upside

Reiterated

07/25/25

Truist Financial Reaffirms Their Hold Rating on Edwards Lifesciences (EW)

Suraj Kalia

Oppenheimer

$90

Buy

10.58%

Upside

Reiterated

07/25/25

Edwards Lifesciences (EW) Gets a Buy from Oppenheimer

Pito Chickering

Deutsche Bank

$85→$94

Buy

15.49%

Upside

Reiterated

07/25/25

Edwards Lifesciences price target raised to $94 from $85 at Deutsche BankEdwards Lifesciences price target raised to $94 from $85 at Deutsche Bank

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Edwards Lifesciences

1 Month

xxx

Success Rate

13/18 ratings generated profit

Average Return

+3.02%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 72.22% of your transactions generating a profit, with an average return of +3.02% per trade.

3 Months

xxx

Success Rate

14/19 ratings generated profit

Average Return

+1.55%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 73.68% of your transactions generating a profit, with an average return of +1.55% per trade.

1 Year

Suraj KaliaOppenheimer

Success Rate

22/32 ratings generated profit

Average Return

+11.69%

reiterated a buy rating 28 days ago

Copying Suraj Kalia's trades and holding each position for 1 Year would result in 68.75% of your transactions generating a profit, with an average return of +11.69% per trade.

2 Years

xxx

Success Rate

15/22 ratings generated profit

Average Return

+14.02%

reiterated a xxx

rating 28 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 68.18% of your transactions generating a profit, with an average return of +14.02% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

EW Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, EW has received 32 Buy Ratings, 22 Hold Ratings, and 0 Sell Ratings. EW average Analyst price target in the past 3 months is 88.86.

Each month's total comprises the sum of three months' worth of ratings.

EW Financial Forecast

EW Earnings Forecast

Next quarter’s earnings estimate for EW is $0.59 with a range of $0.56 to $0.64. The previous quarter’s EPS was $0.67. EW beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 41.67% of the time in the same period. In the last calendar year EW has Outperformed its overall industry.

EW Sales Forecast

Next quarter’s sales forecast for EW is $1.50B with a range of $1.46B to $1.52B. The previous quarter’s sales results were $1.53B. EW beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 51.72% of the time in the same period. In the last calendar year EW has Outperformed its overall industry.

EW Stock Forecast FAQ

What is EW’s average 12-month price target, according to analysts?

Based on analyst ratings, Edwards Lifesciences’s 12-month average price target is 88.86.

What is EW’s upside potential, based on the analysts’ average price target?

Edwards Lifesciences has 9.18% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is EW a Buy, Sell or Hold?

Edwards Lifesciences has a consensus rating of Moderate Buy which is based on 15 buy ratings, 9 hold ratings and 0 sell ratings.

What is Edwards Lifesciences’s price target?

The average price target for Edwards Lifesciences is 88.86. This is based on 24 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $101.00 ,the lowest forecast is $80.00. The average price target represents 9.18% Increase from the current price of $81.39.

What do analysts say about Edwards Lifesciences?

Edwards Lifesciences’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 24 Wall Streets Analysts.

How can I buy shares of EW?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Edwards Lifesciences (EW) Stock Forecast & Price Target

EW Analyst Ratings

EW Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Edwards Lifesciences

EW Analyst Recommendation Trends

EW Financial Forecast

EW Earnings Forecast

EW Sales Forecast

EW Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts